Standard Bariatrics will be at SAGES 2022 in Denver in just a couple of weeks and we hope you’ll stop by booth #513. Surgeons who have been using the Titan SGS® in sleeve gastrectomy will be on site to share how the Titan SGS surgical stapler technology helps achieve more consistent and symmetrical sleeve pouch anatomy.
After Successful Launch of Titan SGS® Surgical Stapler, Standard Bariatrics, Inc. Achieves Final Series B Funding Early
Cincinnati, Ohio – February 28, 2022. Cincinnati-based Standard Bariatrics, Inc., an emerging leader in the bariatric surgery medical device field, today announced completion of a $35 million Series B round ahead of schedule. The successful launch of the Titan SGS® surgical stapler completed the final milestones needed to realize the
Bariatric surgeons are seeing benefits delivered to patients from the anatomy-based approach of Titan SGS® surgical stapler technology from Standard Bariatrics®, Inc. Since the first use in gastric sleeve surgery on August 24, 2021, the Titan SGS has now been used in over 1,000 clinical cases and efficacy data continues to build.
Standard Bariatrics®, Inc. (SBI), a Cincinnati-based company focused on developing medical devices for surgical treatments of obesity, announced it reached a $1M sales milestone during November 2021 for the Titan SGS™, a surgical stapler first used in gastric sleeve surgery on August 24, 2021 following FDA clearance.
This month, the US Food and Drug Administration (FDA) issued guidance on surgical staplers and staples for internal use. Learn more about the new Class II designation for surgical staplers, including the FDA’s recommendation for labeling regarding risks associated with staple line crossing. Titan SGS™ from Standard Bariatrics® was recently cleared by the FDA under the more stringent Class II guidelines.